Skip to main content
. Author manuscript; available in PMC: 2024 Apr 17.
Published in final edited form as: Lancet. 2023 Apr 15;401(10384):1277–1292. doi: 10.1016/S0140-6736(23)00285-4

Figure 4: Subgroup analyses of recurrence with concurrent anthracycline plus docetaxel plus cyclophosphamide versus same dose docetaxel plus cyclophosphamide.

Figure 4:

Subgroup analyses of first invasive recurrence of breast cancer. O–E=observed minus expected. ER=oestrogen receptor. NS=not significant. N0=node-negative. N+=node-positive. PR=progesterone receptor. 2p=two-sided p value.*99% CIs are provided for individual subgroup data; 95% CI is provided for the total data.